MicrobicidesTrial: VOICE (MTN 003)
Phase: IIb, safety and effectiveness
Product being tested: Tenofovir gel; oral TDF; oral TDF/FTC
Sponsor, funder, developer, collaborator: CONRAD, DAIDS/NIAID, Gilead, MTN, NICHD, NIMH
Total participants: 5,000 heterosexual women
Countries: Malawi, South Africa, Uganda, Zimbabwe
Results expected: Ongoing/2013
Partner Treatment